(Q38231432)

31 August 2017

A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. (English)

1 reference

chronic lymphocytic leukemia

31 August 2017

0 references

1 reference

1 reference

Polina Shindiapina

1

1 reference

31 August 2017

Jennifer R Brown

series ordinal

2

1 reference

31 August 2017

Alexey V Danilov

series ordinal

3

1 reference

31 August 2017

language of work or name

English

0 references

publication date

21 July 2014

1 reference

British Journal of Haematology

31 August 2017

1 reference

31 August 2017

167

1 reference

31 August 2017

2

1 reference

31 August 2017

149-161

1 reference

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

31 August 2017

1 reference

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

21 January 2018

1 reference

Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features

21 January 2018

1 reference

Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century

21 January 2018

1 reference

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

21 January 2018

1 reference

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

21 January 2018

1 reference

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death

21 January 2018

1 reference

miR-15 and miR-16 induce apoptosis by targeting BCL2

21 January 2018

1 reference

Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis

21 January 2018

1 reference

MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth

21 January 2018

1 reference

DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance

21 January 2018

1 reference

Toward a cure for chronic lymphocytic leukemia: an attack on multiple fronts

21 January 2018

1 reference

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

21 January 2018

1 reference

Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

21 January 2018

1 reference

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia

21 January 2018

1 reference

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.

21 January 2018

1 reference

Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

21 January 2018

1 reference

The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells

21 January 2018

1 reference

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

21 January 2018

1 reference

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial

21 January 2018

1 reference

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

21 January 2018

1 reference

Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment

21 January 2018

1 reference

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia

21 January 2018

1 reference

Elevated expression of p63 protein in human esophageal squamous cell carcinomas

21 January 2018

1 reference

Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia

21 January 2018

1 reference

Identification of a primary target of thalidomide teratogenicity

21 January 2018

1 reference

Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.

21 January 2018

1 reference

Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia

21 January 2018

1 reference

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

21 January 2018

1 reference

Changing the way we think about chronic lymphocytic leukemia

21 January 2018

1 reference

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

21 January 2018

1 reference

Loss of p53 and altered miR15-a/16-1MCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells

21 January 2018

1 reference

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

21 January 2018

1 reference

Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.

21 January 2018

1 reference

Sex differences in incidence and outcome of chronic lymphocytic leukemia patients

21 January 2018

1 reference

Mutant p53 in cancer: new functions and therapeutic opportunities

21 January 2018

1 reference

Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival

21 January 2018

1 reference

Mutant p53 gain-of-function in cancer

21 January 2018

1 reference

Cloning and functional analysis of human p51, which structurally and functionally resembles p53

21 January 2018

1 reference

Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms.

21 January 2018

1 reference

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial

21 January 2018

1 reference

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide

21 January 2018

1 reference

Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice

21 January 2018

1 reference

Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.

21 January 2018

1 reference

Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).

21 January 2018

1 reference

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

21 January 2018

1 reference

The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.

21 January 2018

1 reference

Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia

21 January 2018

1 reference

Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling

21 January 2018

1 reference

A novel protein with strong homology to the tumor suppressor p53.

21 January 2018

1 reference

TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

ΔNp63 is an ectodermal gatekeeper of epidermal morphogenesis

21 January 2018

1 reference

Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center

21 January 2018

1 reference

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia

21 January 2018

1 reference

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience

21 January 2018

1 reference

High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

21 January 2018

1 reference

A new human p53 homologue

21 January 2018

1 reference

Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.

21 January 2018

1 reference

p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa

21 January 2018

1 reference

Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck

21 January 2018

1 reference

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features

21 January 2018

1 reference

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia

21 January 2018

1 reference

p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities

21 January 2018

1 reference

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

21 January 2018

1 reference

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.

21 January 2018

1 reference

TP53 mutation and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

The frequency ofTP53gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors

21 January 2018

1 reference

p63 and p73 are required for p53-dependent apoptosis in response to DNA damage

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.13042

1 reference

31 August 2017

1 reference